Literature DB >> 27726134

Survival of motor neurone protein is required for normal postnatal development of the spleen.

Alison K Thomson1,2, Eilidh Somers2,3, Rachael A Powis2,3, Hannah K Shorrock2,3, Kelley Murphy4, Kathryn J Swoboda5, Thomas H Gillingwater2,3, Simon H Parson1,2.   

Abstract

Spinal muscular atrophy (SMA), traditionally described as a predominantly childhood form of motor neurone disease, is the leading genetic cause of infant mortality. Although motor neurones are undoubtedly the primary affected cell type, the severe infantile form of SMA (Type I SMA) is now widely recognised to represent a multisystem disorder where a variety of organs and systems in the body are also affected. Here, we report that the spleen is disproportionately small in the 'Taiwanese' murine model of severe SMA (Smn-/- ;SMN2tg/0 ), correlated to low levels of cell proliferation and increased cell death. Spleen lacks its distinctive red appearance and presents with a degenerated capsule and a disorganised fibrotic architecture. Histologically distinct white pulp failed to form and this was reflected in an almost complete absence of B lymphocytes necessary for normal immune function. In addition, megakaryoctyes persisted in the red pulp. However, the vascular density remained unchanged in SMA spleen. Assessment of the spleen in SMA patients with the infantile form of the disease indicated a range of pathologies. We conclude that development of the spleen fails to occur normally in SMA mouse models and human patients. Thus, further analysis of immune function is likely to be required to fully understand the full extent of systemic disease pathology in SMA.
© 2016 Anatomical Society.

Entities:  

Keywords:  SMN; immunity; megakaryocytes; organ pathology; patients

Mesh:

Substances:

Year:  2016        PMID: 27726134      PMCID: PMC5244459          DOI: 10.1111/joa.12546

Source DB:  PubMed          Journal:  J Anat        ISSN: 0021-8782            Impact factor:   2.610


  25 in total

1.  SMN deficiency negatively impacts red pulp macrophages and spleen development in mouse models of spinal muscular atrophy.

Authors:  Marie-Therese Khairallah; Jacob Astroski; Sarah K Custer; Elliot J Androphy; Craig L Franklin; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2017-03-01       Impact factor: 6.150

Review 2.  Advances in therapy for spinal muscular atrophy: promises and challenges.

Authors:  Ewout J N Groen; Kevin Talbot; Thomas H Gillingwater
Journal:  Nat Rev Neurol       Date:  2018-02-09       Impact factor: 42.937

Review 3.  Diverse role of survival motor neuron protein.

Authors:  Ravindra N Singh; Matthew D Howell; Eric W Ottesen; Natalia N Singh
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2017-01-15       Impact factor: 4.490

Review 4.  How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.

Authors:  N N Singh; M D Howell; E J Androphy; R N Singh
Journal:  Gene Ther       Date:  2017-05-09       Impact factor: 5.250

Review 5.  A survey of transcripts generated by spinal muscular atrophy genes.

Authors:  Natalia N Singh; Eric W Ottesen; Ravindra N Singh
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2020-05-06       Impact factor: 4.490

6.  Gender-Specific Amelioration of SMA Phenotype upon Disruption of a Deep Intronic Structure by an Oligonucleotide.

Authors:  Matthew D Howell; Eric W Ottesen; Natalia N Singh; Rachel L Anderson; Ravindra N Singh
Journal:  Mol Ther       Date:  2017-04-13       Impact factor: 11.454

7.  Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy.

Authors:  Aoife Reilly; Marc-Olivier Deguise; Ariane Beauvais; Rebecca Yaworski; Simon Thebault; Daniel R Tessier; Vincent Tabard-Cossa; Niko Hensel; Bernard L Schneider; Rashmi Kothary
Journal:  Gene Ther       Date:  2022-04-25       Impact factor: 4.184

8.  Developmental and degenerative cardiac defects in the Taiwanese mouse model of severe spinal muscular atrophy.

Authors:  Gillian K Maxwell; Eva Szunyogova; Hannah K Shorrock; Thomas H Gillingwater; Simon H Parson
Journal:  J Anat       Date:  2018-02-22       Impact factor: 2.610

Review 9.  Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

Authors:  Natalia N Singh; Shaine Hoffman; Prabhakara P Reddi; Ravindra N Singh
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-05       Impact factor: 5.187

10.  Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice.

Authors:  Kaitlyn M Kray; Vicki L McGovern; Deepti Chugh; W David Arnold; Arthur H M Burghes
Journal:  Neurobiol Dis       Date:  2021-08-20       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.